The protein binding substance Ibuprofen does not affect the T1 time or partition coefficient in contrast-enhanced cardiovascular magnetic resonance
Contrast enhanced cardiovascular magnetic resonance (CMR) with T1 mapping enables quantification of diffuse myocardial fibrosis. Various factors, however, can interfere with T1 measurements. The purpose of the current study was to assess the effect of co-medication with a typical protein binding drug (Ibuprofen) on T1 values in vitro and in vivo.
50 vials were prepared with different concentrations of gadobenate dimeglumine, Ibuprofen and human serum albumin in physiologic NaCl solution and imaged at 1.5T with a spin echo sequence at multiple TRs to measure T1 values and calculate relaxivities. 10 volunteers (5 men; 31±6.3 years) were imaged at 1.5T. T1 values for myocardium and blood pool were determined for various time points after administration of 0.15mmol/kg gadobenate dimeglumine using a modified look-locker inversion-recovery sequence before and after administration of Ibuprofen over 24 hours. The partition coefficient was calculated as ΔR1myocardium/ΔR1blood, where R1=1/T1.
In vitro no significant correlation was found between relaxivity and Ibuprofen concentration, neither in absence (r=−0.15, p=0.40) nor in presence of albumin (r=−0.32, p=0.30). In vivo there was no significant difference in post contrast T1 times of myocardium and blood, respectively and also in the partition coefficient between exam 1 and 2 (p>0.05). There was good agreement of the T1 times of myocardium and blood and the partition coefficient, respectively between exam 1 and 2.
Contrast enhanced T1 mapping is unaffected by co-medication with the protein binding substance Ibuprofen and has an excellent reproducibility.
- Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta SN, Kaye DM, Taylor AJ: Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol 2008, 52:1574–1580. CrossRef
- Been M, Thomson BJ, Smith MA, Ridgway JP, Douglas RH, Best JJ, Muir AL: Myocardial involvement in systemic lupus erythematosus detected by magnetic resonance imaging. Eur Heart J 1988, 9:1250–1256.
- Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, Sheppard MN, Poole-Wilson PA, Hawkins PN, Pennell DJ: Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005, 111:186–193. CrossRef
- Sparrow P, Messroghli DR, Reid S, Ridgway JP, Bainbridge G, Sivananthan MU: Myocardial T1 mapping for detection of left ventricular myocardial fibrosis in chronic aortic regurgitation: pilot study. AJR Am J Roentgenol 2006, 187:W630-W635. CrossRef
- Broberg CS, Chugh SS, Conklin C, Sahn DJ, Jerosch-Herold M: Quantification of diffuse myocardial fibrosis and its association with myocardial dysfunction in congenital heart disease. Circ Cardiovasc Imaging 2010, 3:727–734. CrossRef
- Jellis C, Martin J, Narula J, Marwick TH: Assessment of nonischemic myocardial fibrosis. J Am Coll Cardiol 2010, 56:89–97. CrossRef
- Ng AC, Auger D, Delgado V, van Elderen SG, Bertini M, Siebelink HM, van der Geest RJ, Bonetti C, van der Velde ET, de Roos A, et al.: Association between diffuse myocardial fibrosis by cardiac magnetic resonance contrast-enhanced t1 mapping and subclinical myocardial dysfunction in diabetic patients: a pilot study. Circ Cardiovasc Imaging 2012, 5:51–59. CrossRef
- Messroghli D, Nordmeyer S, Dietrich T, Dirsch O, Kaschina E, Savvatis K: D OHI, Klein C, Berger F, Kuehne T: Assessment of Diffuse Myocardial Fibrosis in Rats Using Small Animal Look-Locker Inversion Recovery (SALLI) T1 Mapping. Imaging: Circ Cardiovasc; 2011.
- Wong TC, Piehler K, Meier CG, Testa SM, Klock AM, Aneizi AA, Shakesprere J, Kellman P, Shroff SG, Schwartzman DS, et al.: Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation 2012, 126:1206–1216. CrossRef
- Gai N, Turkbey EB, Nazarian S, van der Geest RJ, Liu CY, Lima JA, Bluemke DA: T(1) mapping of the gadolinium-enhanced myocardium: Adjustment for factors affecting interpatient comparison. Magn Reson Med 2011, 65:1407–1415. CrossRef
- Kawel N, Nacif M, Santini F, Liu S, Bremerich J, Arai AE, Bluemke DA: Partition coefficients for gadolinium chelates in the normal myocardium: Comparison of gadopentetate dimeglumine and gadobenate dimeglumine. J Magn Reson Imaging 2012, 36:733–777. CrossRef
- Aime S, Caravan P: Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imaging 2009, 30:1259–1267. CrossRef
- Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ: Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005, 40:715–724. CrossRef
- Spinazzi A, Lorusso V, Pirovano G, Kirchin M: Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. Acad Radiol 1999, 6:282–291. CrossRef
- Lauffer RB, Parmelee DJ, Dunham SU, Ouellet HS, Dolan RP, Witte S, McMurry TJ, Walovitch RC: MS-325: albumin-targeted contrast agent for MR angiography. Radiology 1998, 207:529–538.
- Wang Y, Spiller M, Caravan P: Evidence for weak protein binding of commercial extracellular gadolinium contrast agents. Magn Reson Med 2010, 63:609–616. CrossRef
- Messroghli DR, Greiser A, Frohlich M, Dietz R, Schulz-Menger J: Optimization and validation of a fully-integrated pulse sequence for modified look-locker inversion-recovery (MOLLI) T1 mapping of the heart. J Magn Reson Imaging 2007, 26:1081–1086. CrossRef
- Santini FPS, Scheffler K: IceLuva: A scripting framework for MR image reconstruction based on free software. Concepts in Magnetic Resonance Part B: Magnetic Resonance Engineering 2011, 39B:1–10. CrossRef
- Messroghli DR, Rudolph A, Abdel-Aty H, Wassmuth R, Kuhne T, Dietz R, Schulz-Menger J: An open-source software tool for the generation of relaxation time maps in magnetic resonance imaging. BMC Med Imaging 2010, 10:16. CrossRef
- Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, Ryan T, Verani MS: Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002, 105:539–542. CrossRef
- Lee JJ, Liu S, Nacif MS, Ugander M, Kawel N, Sibley CT, Kellman P, Arai A, Bluemke DA: Myocardial T1 and Extracellular Volume Fraction Mapping at 3 Tesla. Journal of cardiovascular magnetic resonance: official journal of the Society for Cardiovascular Magnetic Resonance 2011, 13:75. CrossRef
- Sharma P, Socolow J, Patel S, Pettigrew RI, Oshinski JN: Effect of Gd-DTPA-BMA on blood and myocardial T1 at 1.5T and 3T in humans. J Magn Reson Imaging 2006, 23:323–330. CrossRef
- Spinazzi A, Lorusso V, Pirovano G, Taroni P, Kirchin M, Davies A: Multihance clinical pharmacology: biodistribution and MR enhancement of the liver. Acad Radiol 1998,5(Suppl 1):S86-S89. discussion S93-S84 CrossRef
- Giesel FL, von Tengg-Kobligk H, Wilkinson ID, Siegler P, von der Lieth CW, Frank M, Lodemann KP, Essig M: Influence of human serum albumin on longitudinal and transverse relaxation rates (r1 and r2) of magnetic resonance contrast agents. Invest Radiol 2006, 41:222–228. CrossRef
- Vander Elst L, Laurent S, Bintoma HM, Muller RN: Albumin-bound MRI contrast agents: the dilemma of the rotational correlation time. MAGMA 2001, 12:135–140. CrossRef
- Caravan P: Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action. Acc Chem Res 2009, 42:851–862. CrossRef
- Elsadek B, Kratz F: Impact of albumin on drug delivery - New applications on the horizon. J Control Release 2012, 157:4–28. CrossRef
- Messroghli DR, Plein S, Higgins DM, Walters K, Jones TR, Ridgway JP, Sivananthan MU: Human myocardium: single-breath-hold MR T1 mapping with high spatial resolution–reproducibility study. Radiology 2006, 238:1004–1012. CrossRef
- Kawel N, Nacif M, Zavodni A, Jones J, Liu S, Sibley CT, Bluemke DA: T1 mapping of the myocardium: intra-individual assessment of post-contrast T1 time evolution and extracellular volume fraction at 3T for Gd-DTPA and Gd-BOPTA. J Cardiovasc Magn Reson 2012, 14:26. CrossRef
- The protein binding substance Ibuprofen does not affect the T1 time or partition coefficient in contrast-enhanced cardiovascular magnetic resonance
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Journal of Cardiovascular Magnetic Resonance
- Online Date
- October 2012
- Online ISSN
- BioMed Central
- Additional Links
- Gadobenate dimeglumine
- Diffuse myocardial fibrosis
- Author Affiliations
- 1. Department of Radiology, University Hospital Basel, Petersgraben 4, Basel, 4031, Switzerland
- 2. Radiological Physics, University Hospital Basel, Petersgraben 4, Basel, 4031, Switzerland
- 3. Scientific Affairs, Guerbet Switzerland, Winterthurerstrasse 92, Zurich, 8006, Switzerland